vendredi 8 novembre 2019

Onco Actu du 8 novembre 2019


1. BIOLOGIE



Oxygen-Starved Tumor Cells Have Survival Advantage That Promotes Cancer Spread [Johns Hopkins]











1.1 BIOLOGIE - GÉNOME



Double trouble for cancer gene [Science]










3.1.1 PRÉVENTION - TABAC - E-CIGS



Number of U.S. cases of vaping-related illness tops 2,000 [STAT]











A New Smoking Gadget Says It's Safe. Should You Trust It? [Wired]











Juul Ends E-Cigarette Sales of Mint-Flavored Pods [NY Times]










Juul Labs to stop sales of mint-flavored nicotine pods in U.S [Reuters]











4.12 BIOPSIES LIQUIDES



Theranos redux? Not really. But claim of a ‘simple’ test for breast cancer warrants scrutiny [Health News Review]










4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Cervical Cancer Screening Numbers Drop Off in Women 45-65 [Michigan Health]











4.9 DÉP., DIAG. & PRONO. - SEIN



NSGC Panel Divided on Whether Newly Diagnosed Breast Cancer Patients Should Undergo Panel Testing [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Colorectal Cancers Dial up Mutability in Response to Targeted Treatments [Genome Web]











Cancer Cells Increase DNA Mutations to Evade Treatment [The Scientist]










Revamped cancer drug starves tumors in mice [Science]











Learning to stop cancer at its roots [Baylor College of Medicine]











5.12 IMMUNOTHÉRAPIES



Genetic Variations Help Explain Why Immunotherapy Works Differently in Different People [Memorial Sloan Kettering Cancer Center]










5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



New UK startup pursues off-the-shelf CAR-T, cancer vaccines through 'dark antigens' [EndPoints]











New cell therapy player launches with $57M from marquee investors to go after 'definitive' tumor targets [EndPoints]











5.2 PHARMA



Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation [Takeda]











Declaring topline PhIII win, Takeda revives blockbuster hopes for its troubled multiple myeloma drug [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. [Fierce Pharma]











5.3 TRAITEMENTS - FDA, EMA, NICE...



E-cigs and opioids: The next FDA chief will face several ongoing crises [Nature]











5.4 TRAITEMENTS - ECONOMIE



Value-Based Cancer Care: Paying for Performance [Cancer Research Catalyst]











5.8 ASH



Celgene posts pivotal CAR-T data ahead of FDA filing [Fierce Biotech]











Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout [Biopharma Dive]











5.8.1 ASH - COMMUNIQUÉS



bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition [bluebird bio]











6.1 OBSERVATION



Lung Cancer Incidence in Nonmetropolitan and Metropolitan Counties — United States, 2007–2016 [CDC]











6.10.1 POLITIQUES (USA)



Texas Taxpayers to Give Cancer Research Another $3 Billion [The Scientist]











6.7.1 IA/BIOINFORMATIQUE



HealthX's Bakken: AI Can Unlock Health Data's Potential, But Access Still Difficult [Xconomy]











The FDA needs to set standards for using artificial intelligence in drug development [STAT]











6.7.2 APPLIS



Electronic PROs a Proposed Feature of Successor Model in Oncology Care [AJMC]